Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415568 | 1.00 | EPHX1 (0.43) | EPHX1MCHR1EPHX2CYP2D6KDM1A | |
| SCHEMBL4635146 | 0.79 | EPHX1 (0.45) | EPHX1EPHX2KDM1A | |
| SCHEMBL6419317 | 0.79 | EPHX1 (0.45) | EPHX1EPHX2KDM1A | |
| SCHEMBL14450373 | 0.78 | THRB (0.52) | — | |
| SCHEMBL24033437 | 0.78 | EPHX1 (0.49) | EPHX1PARP1 | |
| SCHEMBL13638962 | 0.77 | EPHX1 (0.47) | EPHX1MCHR1EPHX2KDM1A | |
| SCHEMBL13162268 | 0.77 | EPHX1 (0.47) | EPHX1MCHR1EPHX2KDM1A | |
| SCHEMBL5013508 | 0.75 | EPHX2 (0.47) | EPHX1EPHX2OPRL1 | |
| Hydrochloric Acid SCHEMBL2772564 | 0.75 | EPHX1 (0.46) | EPHX1MCHR1EPHX2CYP2D6KDM1A | |
| SCHEMBL6419218 | 0.74 | EPHX1 (0.45) | EPHX1MCHR1EPHX2CYP2D6KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306123-A1 | NOVEL COMPOUNDS | PFIZER INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306123-A1 | NOVEL COMPOUNDS | PFIZER INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306123-A1 | NOVEL COMPOUNDS | PFIZER INC. (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1638933-B1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2008-06-11 | — | — | EP | disclosed |
| EP-1638933-B1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2008-06-11 | — | — | EP | disclosed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | PFIZER INC | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | AOC3, ADRB3, HTR3C | EPHX1 259/4885MCHR1 194/4885EPHX2 549/4885 |
| US-20080306123-A1 | NOVEL COMPOUNDS | ADRB3, HTR3A, HTR3C | EPHX1 124/4885MCHR1 253/4885EPHX2 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.